Publications by Professor Martin Noble - ePrints

Browsing publications by Professor Martin Noble.

Newcastle Authors	Title	Year
Rhianna Rowland Svitlana Korolchuk Dr Marco Salamina Dr Natalie Tatum Professor Martin Noble et al.	Cryo-EM structure of the CDK2-cyclin A-CDC25A complex	2024
Dr Celine Cano Professor Jane Endicott Dr Ian Hardcastle Dr Claire Jennings Suzanne Kyle et al.	Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile	2024
Dr Martyna Pastok Dr Shannon Turberville Dr Arnaud Basle Professor Martin Noble Professor Jane Endicott et al.	Structural requirements for the specific binding of CRABP2 to cyclin D3	2024
Dr Elaine Willmore Suzanne Kyle Dr Yan Zhao Huw Thomas Dr Kenneth Rankin et al.	Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index	2024
Rhianna Rowland Dr Richard Heath Professor Jane Endicott Professor Martin Noble Dr Marco Salamina et al.	Cryo-EM structure of SKP1-SKP2-CKS1 in complex with CDK2-cyclin A-p27KIP1	2023
Dr Mathew Martin Professor Jane Endicott Professor Martin Noble Dr Natalie Tatum	Crystallographic fragment screening in academic cancer drug discovery	2023
Dr Catherine Salvini Benoit Darlot Jack Davison Dr Mathew Martin Dr Susan Tudhope et al.	Fragment expansion with NUDELs – poised DNA-encoded libraries	2023
Dr Nahoum Anthony Charlotte Jennings Dr Mathew Martin Dr Richard Noble Nicole Phillips et al.	Targeting cytotoxic agents through EGFR-mediated covalent binding and release	2023
Dr Arnaud Basle Professor Martin Noble	The CCP4 suite: integrative software for macromolecular crystallography	2023
Melanie Uguen Gemma Davison James Hunter Dr Mathew Martin Dr Shannon Turberville et al.	Build–Couple–Transform: A paradigm for lead-like library synthesis with scaffold diversity	2022
Dr Mathew Martin Professor Martin Noble	Exiting the tunnel of uncertainty: crystal soak to validated hit	2022
Gemma Davison Dr Mathew Martin Dr Shannon Turberville Selma Dormen Dr Richard Heath et al.	Mapping ligand interactions of bromodomains BRD4 and ATAD2 with FragLites and PepLites ─ Halogenated probes of druglike and peptide-like molecular interactions	2022
Duncan Miller Tristan Reuillon Dr Lauren Molyneux Dr Tim Blackburn Dr Noel Edwards et al.	Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor	2022
Islam Al-Khawaldeh Dr Christine Basmadjian Dr Cinzia Bordoni Dr Suzannah Harnor Amy Heptinstall et al.	An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)	2021
Dr Marco Salamina Dr Richard Heath Svitlana Korolchuk Dr Arnaud Basle Dr Martyna Pastok et al.	Discriminative SKP2 Interactions with CDK-Cyclin Complexes Support a Cyclin A-Specific Role in p27KIP1 Degradation	2021
Dr Ian Hardcastle Dr Ruth Bawn Dr Tim Blackburn Dr Celine Cano Dr Sarah Cully et al.	Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction	2021
Gemma Davison Dr Mathew Martin Professor Martin Noble Professor Mike Waring	Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease	2020
Dr Natalie Tatum Professor Martin Noble	Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors	2020
Professor Martin Noble	Announcing mandatory submission of PDBx/mmCIF format files for crystallographic depositions to the protein data bank (PDB)	2019
Daniel Wood Svitlana Korolchuk Dr Natalie Tatum Lan Wang Professor Jane Endicott et al.	Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition	2019
Daniel Wood Daniel Lopez Fernandez Leanne Knight Islam Al-Khawaldeh Dr Conghao Gai et al.	FragLites - minimal, halogenated fragments displaying pharmacophore doublets. An efficient approach to druggability assessment and hit generation	2019
Stephanie Myers Duncan Miller Dr Lauren Molyneux Dr Mercedeh Arasta Dr Ruth Bawn et al.	Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4	2019
Dr Claire Jennings Dr Judith Reeks Jieman Meng Professor Martin Noble	Tuning the binding affinity and selectivity of perfluoroaryl-stapled peptides by cysteine-editing	2019
Duncan Miller Dr Mathew Martin Santosh Adhikari Alfie Brennan Professor Jane Endicott et al.	Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach	2018
Dr Mathew Martin Professor Martin Noble	Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor	2018
Judith Unterlass Dr Arnaud Basle Dr Julie Tucker Dr Celine Cano Professor Martin Noble et al.	Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer	2018
Dr Dominic Jones Professor Martin Noble Professor Steve Wedge Professor Craig Robson Dr Luke Gaughan et al.	Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer	2017
Christopher Coxon Dr Suzannah Harnor Dr Mathew Martin Dr Benoit Carbain Emeritus Professor Bernard Golding et al.	Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines	2017
Stephen Hallett Dr Martyna Pastok Dr Anita Wittner Professor Steve Wedge Professor Martin Noble et al.	Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System	2017
Professor David Rees Emeritus Professor Bernard Golding Dr Ian Hardcastle Dr Celine Cano Duncan Miller et al.	ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY	2017
Professor David Rees Emeritus Professor Bernard Golding Dr Ian Hardcastle Dr Celine Cano Duncan Miller et al.	Preparation of isoindolinones as inhibitors of the MDM2-p53 interaction having anticancer activity	2017
Professor David Rees Emeritus Professor Bernard Golding Dr Ian Hardcastle Dr Celine Cano Duncan Miller et al.	Preparation of isoindolinones as inhibitors of the MDM2-p53 interaction having anticancer activity;WO 2017055860	2017
Judith Unterlass Dr Arnaud Basle Dr Julie Tucker Dr Celine Cano Professor Martin Noble et al.	Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH)	2017
Dr Mathew Martin Professor Jane Endicott Professor Martin Noble	Structure-based discovery of cyclin-dependent protein kinase inhibitors	2017
Dr Judith Reeks Dr Claire Jennings Professor Martin Noble	Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design	2016
Tristan Reuillon Duncan Miller Stephanie Myers Dr Lauren Molyneux Dr Celine Cano et al.	Pyrrolcarboxamide Derivatives for the Inhibition of ERK5	2016
Svitlana Korolchuk Dr Mathew Martin Dr Will Stanley Professor Martin Noble Professor Jane Endicott et al.	CDK1 structures reveal conserved and unique features of the essential cell cycle CDK	2015
Elisa Meschini Dr Regina Mora Vidal Dr Mathew Martin Dr Will Stanley Tristan Reuillon et al.	Identification and characterization of an irreversible inhibitor of CDK2	2015
Bailey Massa Dr Mathew Martin Professor Martin Noble Professor Jane Endicott	Structural and functional characterization of Skp2-containing complexes	2015
Judith Unterlass Nabila Aljufri Sophie Bex Dr Celine Cano Professor Martin Noble et al.	Towards structure-based drug design of 3-phosphoglycerate dehydrogenase inhibitors	2015
Dr Benoit Carbain Dr Allyson Campbell Dr Celine Cano Professor Jane Endicott Emeritus Professor Bernard Golding et al.	8-Substituted O-6-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode	2014
Dr Alison Hole Professor Jane Endicott Professor Martin Noble	An Inhibitor's-Eye View of the ATP-Binding Site of CDKs in Different Regulatory States	2014
Alex Liu Dr Catherine Drummond Professor Jane Endicott Emeritus Professor Bernard Golding Professor Roger Griffin et al.	An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinones	2014
Honorine Lebraud Emeritus Professor Bernard Golding Elisa Meschini Dr Celine Cano Lan Wang et al.	Anticancer agents targeted against cyclin-dependent kinase 2 (CDK2): Structure-based design of irreversible and reversible inhibitors	2014
Andrew Shouksmith Laura Evans Professor Roger Griffin Emeritus Professor Bernard Golding Professor Herbie Newell et al.	Design and synthesis of putative small-molecule inhibitors targeting the SCFSKP2 E3 ligase complex	2014
Dr Mathew Martin Elisa Meschini Lan Wang Dr Regina Mora Vidal Tristan Reuillon et al.	Identification and characterization of an irreversible inhibitor of CDK2	2014
Dr Alison Hole Dr Sonja Baumli Professor Jane Endicott Professor Martin Noble	Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity	2013
Professor Martin Noble	Mechanisms of Site-Specific Functions of Focal Adhesion Kinase	2013
Sarah Cully Dr Celine Cano Emeritus Professor Bernard Golding Professor Roger Griffin Professor John Lunec et al.	Regiospecific synthesis of isoindolinones as MDM2 inhibitors	2013
Professor Jane Endicott Professor Martin Noble	Structural characterization of the cyclin-dependent protein kinase family	2013
Professor Martin Noble Professor Jane Endicott	Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure-Activity Relationship, and Anticancer Activities	2013
Professor Jane Endicott Professor Martin Noble	The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant	2013
Professor Martin Noble	Generation of protein lattices by fusing proteins with matching rotational symmetry	2012
Professor Martin Noble Professor Jane Endicott	Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation	2012
Dr Sonja Baumli Dr Alison Hole Professor Martin Noble Professor Jane Endicott	The CDK9 C-helix Exhibits Conformational Plasticity That May Explain the Selectivity of CAN508	2012
Dr Sonja Baumli Dr Alison Hole Lan Wang Professor Martin Noble Professor Jane Endicott et al.	The CDK9 Tail Determines the Reaction Pathway of Positive Transcription Elongation Factor b	2012
Professor Jane Endicott Professor Martin Noble	The Structural Basis for Control of Eukaryotic Protein Kinases	2012
Professor Martin Noble	Catalysis and regulation.	2011
Dr Ian Hardcastle Alex Liu Dr Eric Valeur Anna Watson Shafiq Ahmed et al.	Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-Activity Studies Leading to Improved Potency	2011
Dr Karim Bennaceur Dr Catherine Drummond Professor Jane Endicott Emeritus Professor Bernard Golding Professor Roger Griffin et al.	MDM2-p53 protein-protein interaction inhibitors: A-ring substituted isoindolinones	2011
Professor Martin Noble Dr Ian Hardcastle Professor Jane Endicott	Understanding small-molecule binding to MDM2: Insights into structural effects of isoindolinone inhibitors from NMR spectroscopy	2011
Professor Martin Noble Professor Jane Endicott	A new crystal form of Lys48-linked diubiquitin	2010
Elisa Meschini Professor Jane Endicott Emeritus Professor Bernard Golding Dr Ian Hardcastle Professor Herbie Newell et al.	Design and synthesis of dual CDK2 and CDK7 inhibitors	2010
Professor Martin Noble	Distinctive Properties of the Hyaluronan-binding Domain in the Lymphatic Endothelial Receptor Lyve-1 and Their Implications for Receptor Function	2010
Professor Jane Endicott Professor Martin Noble	Recent developments in cyclin-dependent kinase biochemical and structural studies	2010
Professor Martin Noble	Structural Studies on the Mycobacterial Arylamine N-Acetyltransferases	2010
Professor Martin Noble Professor Jane Endicott	Structure of Rpn10 and Its Interactions with Polyubiquitin Chains and the Proteasome Subunit Rpn12	2010
Dr Benoit Carbain Dr Celine Roche Emeritus Professor Bernard Golding Dr Ian Hardcastle Dr Celine Cano et al.	Structure-based design of C8-substituted O6-alkylguanine CDK1 and 2 inhibitors	2010
Professor Jane Endicott Professor Martin Noble	The structure of CDK4/cyclin D3 has implications for models of CDK activation	2009
Professor Jane Endicott Stuart Kemp Dr Lucy Smyth Dr Eric Valeur Emeritus Professor Bernard Golding et al.	Analysis of Chemical Shift Changes Reveals the Binding Modes of Isoindolinone Inhibitors of the MDM2-p53 Interaction	2008
Professor Martin Noble	Arylamine N-acetyltransferases in mycobacteria	2008
Professor Martin Noble	Divergence of cofactor recognition across evolution: Coenzyme a binding in a prokaryotic arylamine N-acetyltransferase	2008
Professor Martin Noble	Structural Analysis of the Interactions Between Paxillin LD Motifs and α-Parvin	2008
Professor Martin Noble	Structure of HsaD, a steroid-degrading hydrolase, from Mycobacterium tuberculosis	2008
Professor Martin Noble Professor Jane Endicott	Structures of P. falciparum protein kinase 7 identify an activation motif and leads for inhibitor design	2008
Professor Martin Noble	Expression and functional characterization of the G1 domain from human versican	2007
Dr Julie Tucker Professor Martin Noble Professor Jane Endicott	How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A	2007
Professor Martin Noble	Molecular cloning, characterisation and ligand-bound structure of an azoreductase from Pseudomonas aeruginosa	2007
Professor Martin Noble Anthony Day	Plasticity of the TSG-6 HA-binding loop and mobility in the TSG-6-HA complex revealed by NMR and X-ray crystallography	2007
Dr Francesco Marchetti Kerry Louise Sayle Dr Johanne Bentley Professor William Clegg Professor Nicola Curtin et al.	Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6- aminopyrimidine inhibitors of cyclin-dependent kinase 2	2007
Professor Martin Noble	Structures of the Cd44-hyaluronan complex provide insight into a fundamental carbohydrate-protein interaction	2007
Dr Johanne Bentley Professor Jane Endicott Professor Martin Noble	Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity	2006
Professor Roger Griffin Andrew Henderson Professor Nicola Curtin Professor Jane Endicott Dr Ian Hardcastle et al.	Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination	2006
Professor Jane Endicott Professor Martin Noble	Structure-based protein kinase inhibitor design	2006
Professor Martin Noble Professor Jane Endicott	Structures of the Dsk2 UBL and UBA domains and their complex	2006
Professor Martin Noble	The role of the phospho-CDK2/cyclin A recruitment site in substrate recognition	2006
Professor Martin Noble	Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis	2005
Professor Martin Noble Professor Jane Endicott	Exploiting structural principles to design cyclin-dependent kinase inhibitors	2005
Professor Martin Noble	Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase	2005
Dr Ian Hardcastle Shafiq Ahmed Emeritus Professor Bernard Golding Professor Roger Griffin Dr Claire Hutton et al.	Inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold	2005
Professor Martin Noble	Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines	2005
Stuart Kemp Dr Ian Hardcastle Dr Shafiq Ahmed Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Isoindolinone based inhibitors of the MDM2-p53 protein-protein interaction	2005
Professor Martin Noble Professor Jane Endicott	Mechanism of Lys48-linked polyubiquitin chain recognition by the Mud1 UBA domain	2005
Professor Martin Noble Professor Jane Endicott	Molecular basis for the recognition of phosphorylated and phosphoacetylated histone H3 by 14-3-3	2005
Professor Roger Griffin Dr YuZhu Cheng Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	Potent CDK2 inhibitors generated using a variant of the cope elimination	2005
Andrew Henderson Dr YuZhu Cheng Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Searching for potent CDK2 inhibitors using a variant of the Cope elimination	2005
Professor Martin Noble	Structure of Mesorhizobium loti arylamine N-acetyltransferase 1	2005
Professor Martin Noble	Arylamine N-acetyltransferase from Mycobacterium smegmatis; An isoniazid metabolising enzyme in action	2004
Professor Martin Noble	Developments in the CCP4 molecular-graphics project	2004
Dr Ian Hardcastle Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin Professor Jane Endicott et al.	N2-substituted O6-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 2	2004
Professor Martin Noble Professor Jane Endicott	Protein kinase inhibitors: Insights into drug design from structure	2004
Professor Martin Noble	Structure of the regulatory hyaluronan binding domain in the inflammatory leukocyte homing receptor CD44	2004
Professor Jane Endicott Professor Martin Noble	The role of structure in kinase-targeted inhibitor design	2004
Dr Veronique Mesguiche Rachel Parsons Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin et al.	4-Alkoxy-2,6-diaminopyrimidine derivatives: Inhibitors of cyclin dependent kinases 1 and 2	2003
Professor Martin Noble Professor Jane Endicott	Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects	2003
Professor Martin Noble	Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function	2003
Professor Jane Endicott Professor Martin Noble	Molecular recognition of indigoids	2003
Professor Martin Noble	Molecular recognition of paxillin LD motifs by the focal adhesion targeting domain	2003
Professor Martin Noble	Structural investigation of mutant Mycobacterium smegmatis arylamine N-acetyltransferase: a model for a naturally occurring functional polymorphism in Mycobacterium tuberculosis arylamine N-acetyltransferase	2003
Kerry Louise Sayle Dr Johanne Bentley Professor Alan Calvert Dr YuZhu Cheng Professor Nicola Curtin et al.	Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2	2003
Professor Martin Noble Professor Jane Endicott	Structures of P-falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition	2003
Kerry Louise Sayle Dr Veronique Mesguiche Rachel Parsons Professor Jane Endicott Professor Martin Noble et al.	4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2	2002
Dr Ashleigh Gibson Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin Professor Jane Endicott et al.	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O6-substituted guanine derivatives	2002
Professor Martin Noble	Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4	2002
Professor Martin Noble	Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A	2002
Professor Jane Endicott Professor Martin Noble	Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2	2002
Dr Johanne Bentley Dr Christine Arris Professor Nicola Curtin Professor Jane Endicott Dr Ashleigh Gibson et al.	Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor	2002
Professor Jane Endicott Professor Martin Noble	Structure-based design of cyclin-dependent kinase inhibitors	2002
Professor Martin Noble	The structure of arylamine N-acetyltransferase from mycobacterium smegmatis - An enzyme which inactivates the anti-tubercular drug, Isoniazid	2002
Professor Jane Endicott Professor Martin Noble	Xenopus phospho-CDK7/cyclin H expressed in baculoviral-infected insect cells	2001
Professor Jane Endicott Professor Martin Noble	Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate	2001
Professor Martin Noble	Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with PhosphoCDK2	2001
Professor Martin Noble Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson et al.	Structural and thermodynamic validation of inactive cdk2 as a template for structure-based drug design	2001
Professor Martin Noble Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Structure based design of a potent inhibitor of cdk2	2001
Professor Martin Noble	The role of the Src homology 3-Src homology 2 interface in the regulation of Src kinases	2001
Professor Martin Noble	An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes	2000
Professor Martin Noble Professor Jane Endicott	Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex	2000
Professor Roger Griffin Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson et al.	Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors	2000
Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Professor Jane Endicott Emeritus Professor Bernard Golding et al.	Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles	2000
Professor Martin Noble	Structure of arylamine N-acetyltransferase reveals a catalytic triad	2000
Dr Johanne Bentley Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Professor Jane Endicott et al.	Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors	2000
Professor Herbie Newell Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson et al.	Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.	1999
Professor Martin Noble	Catalytic Mechanism of Phosphorylase Kinase Probed by Mutational Studies	1999
Professor Martin Noble Professor Jane Endicott	Chemical inhibitors of cyclin-dependent kinases: Insights into design from X-ray crystallographic studies	1999
Professor Jane Endicott Professor Martin Noble Dr Julie Tucker	Cyclin-dependent kinases: inhibition and substrate recognition	1999
Professor Martin Noble Professor Jane Endicott	Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity	1999
Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson Emeritus Professor Bernard Golding et al.	In vitro growth activity of novel purine- and pyrimidine-based CDK1 and CDK2 inhibitors.	1999
Professor Jane Endicott Professor Martin Noble	Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases	1999
Professor Martin Noble Professor Jane Endicott	Signal transduction proteins: Structural basis of control by phosphorylation	1999
Professor Martin Noble Professor Jane Endicott	The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases	1999
Professor Jane Endicott Professor Martin Noble Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Insights into CDK inhibitor design from X-ray crystallographic studies	1998
Professor Alan Calvert Professor Nicola Curtin Professor Jane Endicott Emeritus Professor Bernard Golding Professor Roger Griffin et al.	O-6-alkylguanines as selective inhibitors of cyclin dependent kinases	1998
Professor Jane Endicott Professor Martin Noble	Structural principles in cell-cycle control: beyond the CDKs	1998
Professor Martin Noble Professor Jane Endicott	Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2	1997
Professor Martin Noble Professor Jane Endicott	The cyclin box fold: protein recognition in cell-cycle and transcription control	1997
Professor Jane Endicott Professor Martin Noble	The structural basis for control by phosphorylation	1997
Professor Jane Endicott Professor Martin Noble	Crystal structure of the cell cycle-regulatory protein suc1 reveals a beta-hinge conformational switch	1995
Professor Martin Noble Professor Jane Endicott	The crystal structure of Cyclin A	1995
Professor Jane Endicott Professor Martin Noble	The crystal structure of p13suc1, a p34cdc2-interacting cell cycle control protein	1995